AZN Stock Price Today (October 2026) — AstraZeneca PLC Analysis & Key Metrics 2026-10-21
AstraZeneca PLC (AZN) is trading at $168.82, up 2.97% today (as of October 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $207.16 (22.7% upside).
- Volatility is low (22.35% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.40% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
AZN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
AstraZeneca PLC - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $289.21B
P/E Ratio
Forward P/E: 14.27
Revenue Growth
Year over Year
Analyst Target
+22.7% upside potential
Key Investor Questions About AZN
What investors need to know before buying
Based on current market data, AZN presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 63.04)
- Fundamentals say: Looking solid (debt and growth supportive)
AZN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AZN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $32.35B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AZN stock traded between $153.41 and $212.71 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 22.35% annualized volatility and β=0.31, the stock exhibits low sensitivity to market moves—making AZN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Sector Update: Healthcare Stocks Gain Late Afternoon
AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
Oracle Stocks Rise 2.4% as AstraZeneca Pact Opens an AI Healthcare Test
Sector Update: Healthcare
AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple?
Oracle (ORCL) Expands Its AI Healthcare Push With A New Drugmaker Partnership
Latest TickZen Insights
All insights →No TickZen article on AZN yet. Our newest analysis:
Explore More Analysis for AZN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 30, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about AstraZeneca PLC
AstraZeneca PLC (AZN) is currently trading at $168.82. The RSI (14-day) is at 63.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $207.16 implies 22.7% upside from current levels. Volatility is moderate at 22.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AstraZeneca PLC (AZN): The trailing P/E ratio is 24.48, which is in line with broader market averages. The forward P/E is 14.27, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.42, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 5.05. Price-to-Sales is 4.14. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering AZN, the consensus price target is $207.16. This represents a 22.7% upside from the current price of $168.82. The range spans from a low target of $158.00 to a high target of $240.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AstraZeneca PLC (AZN) pays a dividend with a current yield of approximately 2.06%. The annualized dividend rate is $3.23 per share. The payout ratio is 46.9%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 7, 2026.
Key risks for AstraZeneca PLC (AZN) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AstraZeneca PLC's (AZN) current debt and financial health profile: Total debt stands at $32.35B. The debt-to-equity ratio is 0.64x, which is moderate and generally manageable for most companies. The current ratio is 0.89, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.66. The company holds $4.97B in cash and equivalents. Free cash flow is positive at $4.91B, providing a cushion for debt servicing and shareholder returns.